<div id="readability-page-1"><div><ul> <li>In March 2026, Takeda and Protagonist Therapeutics announced that the FDA had accepted and granted Priority Review to their New Drug Application for rusfertide, a first-in-class hepcidin mimetic peptide for adults with polycythemia vera, with a PDUFA target action date in the third quarter of this year.</li> <li>This filing, backed by Phase 3 VERIFY and long-term Phase 2 REVIVE and THRIVE data and multiple expedited regulatory designations, positions rusfertide as a potential new option for improving hematocrit control and reducing phlebotomy burden in a disease with serious thrombotic risks.</li> <li>Next, we’ll examine how the Priority Review for rusfertide reshapes Protagonist Therapeutics’ investment narrative and risk‑reward profile for investors.</li> </ul><p>Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.</p><h2>What Is Protagonist Therapeutics' Investment Narrative?</h2><p>To own Protagonist Therapeutics today, you really have to believe rusfertide can anchor a viable commercial franchise and validate the company’s peptide platform, while management steers through a period of ongoing losses. The FDA’s Priority Review meaningfully sharpens the near term story: the Q3 PDUFA date is now the dominant catalyst, with the potential to reshape Protagonist’s cash flow outlook and its collaboration economics with Takeda if approval and launch go smoothly. At the same time, the company is still burning cash, reported a US$130.15 million net loss in 2025, and trades on expectations that are already reflected in a strong one year share price move. The key risk is that any regulatory setback or a slower than hoped uptake for rusfertide would leave investors refocusing quickly on funding needs and pipeline execution.</p><p> However, one near term funding and dilution risk is easy to underestimate before digging into the details.  Protagonist Therapeutics' shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.</p><h2>Exploring Other Perspectives</h2><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/fc7d3f36-7789-4a40-8892-bf2ab67f8e26/chart/quote-price?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/fc7d3f36-7789-4a40-8892-bf2ab67f8e26/chart/quote-price"/><figcaption>PTGX 1-Year Stock Price Chart</figcaption></figure><p> Two Simply Wall St Community fair value views span roughly US$108 to a very large US$354 per share, underlining how differently investors can frame Protagonist’s prospects. When you set that against a business still loss making and now hinging heavily on a single Q3 regulatory decision, it becomes clear why taking in several viewpoints before forming your own stance really matters.</p><p>Explore 2 other fair value estimates on Protagonist Therapeutics - why the stock might be worth just $107.83!</p><h2>Reach Your Own Conclusion</h2><p>Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.</p><ul><li>A great starting point for your Protagonist Therapeutics research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.</li><li>Our free Protagonist Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Protagonist Therapeutics' overall financial health at a glance.</li></ul><h2>Curious About Other Options?</h2><p>Our top stock finds are flying under the radar-for now. Get in early:</p><ul><li>Invest in the nuclear renaissance through our list of 85 elite nuclear energy infrastructure plays powering the global AI revolution.</li><li>Find 49 companies with promising cash flow potential yet trading below their fair value.</li><li>Capitalize on the AI infrastructure supercycle with our selection of the 35 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>• Connect an unlimited number of Portfolios and see your total in one currency<br/>• Be alerted to new Warning Signs or Risks via email or mobile<br/>• Track the Fair Value of your stocks<br/></p><p>Try a Demo Portfolio for Free</p></div></div></div>

<p>In March 2026, the FDA granted Priority Review for Protagonist Therapeutics' rusfertide, a hepcidin mimetic peptide for polycythemia vera, with a PDUFA date in Q3. This development could reshape Protagonist's investment narrative, as the company faces ongoing losses and a significant reliance on this regulatory decision. While shares have risen, they may still be undervalued, with fair value estimates ranging from US$108 to US$354. Investors must consider the risks of regulatory setbacks and the company's financial health before making decisions.</p>

Simplywall

VG Health

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

Protagonist Therap

iShares Global Healthcare

iShares US Pharma

SPDR S&P Biotech

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

Health Care Select Sector SPDR

Ark Genomic Revolution ETF

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

Does FDA Priority Review For Rusfertide Transform The Bull Case For Protagonist Therapeutics (PTGX)?